A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.

doi:10.1016/j.jtho.2021.11.025

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2022

Cho Byoung Chul, Han Ji-Youn, Kim Sang-We, Lee Ki Hyeong, Cho Eun Kyung, Lee Yun-Gyoo, Kim Dong-Wan, Kim Joo-Hang, Lee Gyeong-Won, Lee Jong-Seok, Shim Byoung Yong, Kim Jin-Soo, Chun Sang Hoon, Lee Sung Sook, Kim Hye Ryun, Hong Min Hee, Ahn Jin Seok, Sun Jong-Mu, Lee Youngjoo, Lee Dae Ho, Kang Ji Ah, Lee NaMi, Kwon Mi-Jung, Espenschied Carin, Yablonovitch Arielle, Ahn Myung-Ju

Abstract excerpt

INTRODUCTION: This integrated analysis of a phase 1/2 study (NCT03046992) evaluated the efficacy and safety of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), in patients with advanced EGFR T790M-positive NSCLC after previous EGFR TKI therapy. METHODS: Adults with EGFR mutation-positive NSCLC that progressed after prior EGFR-directed TKIs received once daily oral lazertinib 240 mg...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Morpholines

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Pyrimidines

Source

Open in PubMed

Identifiers

PMID: 34958928
DOI: 10.1016/j.jtho.2021.11.025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.PMID 34958928Read ↗

Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study.Semantic proximity Read ↗

Real-world study of lazertinib as second-line or greater treatment in advanced non-small cell lung cancer.Semantic proximity Read ↗

Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.Semantic proximity Read ↗

Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.Semantic proximity Read ↗

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.Semantic proximity Read ↗

Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A.Semantic proximity Read ↗

Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.Semantic proximity Read ↗

Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial.Semantic proximity Read ↗

Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.Semantic proximity Read ↗

Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment-naive patients with advanced EGFR mutation-positive non-small cell lung cancer: Protocol of an open-label, single-arm phase II trial.Semantic proximity Read ↗

Lazertinib: on the Way to Its Throne.Semantic proximity Read ↗

Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.